COMP <GO>
IQV vs CRL // RETURN ON INVESTED CAPITAL (ROIC)
IQVIA Holdings Inc. (NYSE) VS. Charles River Laboratories International Inc. (NYSE) • 15-METRIC TALLY: IQV 8
— CRL 3
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: IQV
LAST: $267.33 (-2.81%) • MKT CAP: $45.33B
roic
9.40%
LAST: $359.41 (-4.44%) • MKT CAP: $17.95B
roic
0.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IQV VS. CRL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IQV | CRL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 9.40% | 0.40% | +9.00 | IQV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.4x | 95.0x | -74.60 | IQV | /valuation <GO> |
| Free Cash Flow Yield | 4.24% | 3.10% | +1.14 | IQV | /fcf-yield <GO> |
| Operating Margin | 13.40% | 0.60% | +12.80 | IQV | /operating-margins <GO> |
| Net Profit Margin | 8.30% | -3.60% | +11.90 | IQV | /net-margins <GO> |
| Revenue Growth (YoY) | 5.90% | -0.90% | +6.80 | IQV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.22 | 3.65 | -1.43 | CRL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.7 | 72.7 | -17.00 | CRL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 1.15 | +0.01 | IQV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 23.0x | +8.00 | CRL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.33B | $17.95B | $27.38B | IQV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IQV REV | CRL REV | IQV GROSS % | CRL GROSS % | IQV FCF | CRL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $16.31B | $4.02B | — | — | $1.92B | $557.0M |
| FY 2024 | $15.40B | $4.05B | — | — | $2.02B | $552.3M |
| FY 2023 | $14.98B | $4.13B | — | — | $1.47B | $498.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IQV // BETA 1.16
CRL // BETA 1.15